Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis

Diabetes Obes Metab. 2023 Apr;25(4):1130-1135. doi: 10.1111/dom.14957. Epub 2023 Jan 17.

Authors

Juris J Meier¹, Lars Bardtrum², Alice Y Y Cheng³, Brian Malling², Eduard Montanya⁴, Lily Wagner², Richard E Pratley⁵

Affiliations

¹ Department of Internal Medicine, Gastroenterology and Diabetology, Augusta Clinic, Bochum, Germany.
² Novo Nordisk A/S, Søborg, Denmark.
³ Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada.
⁴ Hospital Universitari Bellvitge-IDIBELL CIBERDEM, and University of Barcelona, Barcelona, Spain.
⁵ AdventHealth Translational Research Institute, Orlando, Florida, USA.

PMID: 36562481
DOI: 10.1111/dom.14957

No abstract available

Keywords: GLP-1 analogue; incretin therapy; phase 3 study; type 2 diabetes.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Body Weight
Diabetes Mellitus, Type 2* / chemically induced
Glucagon-Like Peptides / adverse effects
Humans
Hypoglycemic Agents / adverse effects
Weight Loss

Substances

semaglutide
Glucagon-Like Peptides
Hypoglycemic Agents